Prenuvo, a Redwood City, CA-based proactive whole-body MRI screening company, raised $120M in funding.
The round was led by Forerunner Ventures, Left Lane Capital, and existing investor Felicis.
The company intends to use the funds to expand operations and its development efforts.
Building on this momentum, Prenuvo introduced three major advances:
- FDA-cleared, AI-powered whole-body composition analysis platform that is non-invasive and delivers precise, actionable, and quantitative data on visceral fat, subcutaneous fat, liver fat, muscle volumes, as well as the volume of vital abdominal organs – providing patients with a personalized report to make informed lifestyle choices and proactive health decisions.
- New brain health scan that equips patients with critical data on brain function, cognitive health, and early indicators of neurodegenerative conditions.
- Comprehensive functional and conventional blood bio-marker assessment that uses a custom built panel of blood tests to provide insights into metabolic, cardiovascular, hormonal, and immune health. Designed to work symbiotically with imaging to deepen health insights.
Led by CEO Andrew Lacy, Prenuvo makes MRI scanning for early detection of many types of cancer, “silent killers” like aneurysms, and other diseases. Combining analysis technology with radiation-free and non-invasive full-body scans, its patient-centric design is optimized to assess the body holistically and in under 60 minutes. It is also the administrative and managerial services company for the affiliated Prenuvo physician-owned professional corporations that deliver medical services in-office and virtually.
FinSMEs
14/02/2025